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Abstract
The neurodegenerative disorder Huntington disease (HD) is caused by an expanded CAG repeat in 
the huntingtin gene, resulting in loss of striatal and cortical neurons. Although, the gene product is 
widely expressed, it remains unclear why neurons are selectively targeted. Here, we demonstrate 
the relationship between synaptic and extrasynaptic activity, inclusion formation of mutant 
huntingtin protein (mtHtt), and neuronal survival. Synaptic NMDA receptor (NMDAR) activity 
induces mtHtt inclusions via a TCP1 ring complex (TRiC)-dependent mechanism, rendering 
neurons more resistant to mtHtt-mediated cell death. In contrast, stimulation of extrasynaptic 
NMDARs increases vulnerability of mtHtt-neurons to cell death by impairing a neuroprotective 
CREB—PGC-1α cascade and increasing the small guanine nucleotide-binding protein Rhes, 
which is known to sumoylate and disaggregate mtHtt. Treatment of transgenic YAC128 HD mice 
with low-dose memantine blocks extrasynaptic (but not synaptic) NMDARs and ameliorates 
neuropathological and behavioral manifestations. By contrast, high-dose memantine also blocks 
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synaptic NMDAR activity, decreases neuronal inclusions, and worsens these outcomes. Our 
findings offer a rational therapeutic approach for protecting susceptible neurons in HD.
Huntington disease (HD) is an inherited neurodegenerative disorder caused by an expansion 
of a polyglutamine repeat in the N-terminal region of huntingtin1. Aggregation of mutant 
huntingtin (mtHtt) into insoluble macro inclusions, and early selective cell death of striatal 
and cortical neurons are features of the disease2. Interestingly, most if not all 
neurodegenerative disorders, whether or not genetically inherited like HD, manifest 
abnormal misfolded proteins3. Although it has been known for many years that excessive 
NMDAR activity can mimic HD4 and that such activity might contribute to disease 
pathogenesis5-7, it remains unknown if normal synaptic activity influences inclusion 
formation and neuronal survival. Additionally, mechanistic details relating 
electrophysiological activity and molecular pathways to protein misfolding and aggregation 
in disorders such as HD have been lacking. Moreover, a mechanism-based treatment has not 
yet proven successful in HD patients.
RESULTS
NMDA receptor-mediated synaptic activity is necessary for inclusion formation by mtHtt
To investigate the relationship between synaptic activity, inclusion formation and 
neurotoxicity induced by mtHtt, we initially used a neuronal cell culture model of HD in 
which primary striatal or cortical neurons were transiently transfected with constructs of 
either full-length or N-terminal Htt encoding wild-type or expanded polyglutamine repeats. 
Neurons transfected with wtHtt displayed diffuse cytoplasmic expression of huntingtin by 
immunocytochemistry, while both intranuclear and cytoplasmic/neuropil macroscopic 
inclusions were present in neurons transfected with mtHtt (Fig. 1a, b for cortical neurons 
and Supplementary Fig. 1a, b online for striatal neurons). Strikingly, when endogenous 
NMDAR activity was curtailed in these cultures with NMDAR antagonists D-(-)-2 amino-5-
phosphonovaleric acid (D-APV), memantine or ifenprodil, we observed a significant 
decrease in the number of mtHtt-containing inclusions. In contrast, the AMPA (α-amino-3-
hydroxy-5-methyl-4-isooxazole propionic acid)-sensitive glutamate receptor antagonist, 6-
cyano-7-nitroquinoxaline-2, 3-dione (CNQX), did not affect inclusion formation. Moreover, 
neither CNQX nor NMDAR antagonists had any effect on normal huntingtin expression in 
transfected neurons (Supplementary Fig. 2 online). Hence, the suppressive effect of 
NMDAR antagonists on mtHtt inclusion formation could not be attributed to a global 
suppression of protein expression. Importantly, memantine decreased mtHtt-containing 
inclusions only at high (30 μM) concentrations, but not at lower (≤10 μM) concentrations 
(Fig. 1a, b; Supplementary Fig. 1a, b). To mimic more closely the pathophysiological 
situation, we next utilized neurons transfected with full-length mtHtt bearing a 44Q 
expansion, or neurons from the striatum of the transgenic YAC128 HD mouse, which has a 
yeast artificial chromosome (YAC) encoding the entire human HD gene containing 128 
CAG repeats8. These models produced similar findings (Supplementary Figs. 3 and 4 
online).
Okamoto et al. Page 2
Nat Med. Author manuscript; available in PMC 2010 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Unlike other NMDAR antagonists, such as ifenprodil and D-APV, we have shown that 
memantine is an open-channel blocker, acting via an uncompetitive/fast ‘off-rate’ 
mechanism whereby low micromolar concentrations of the drug preferentially inhibit 
excessive, primarily extrasynaptic, stimulation of NMDARs but relatively preserve 
physiological synaptic transmission9,10. In contrast, higher concentrations of memantine 
lose this selectivity and also inhibit normal NMDAR-mediated synaptic activity like other 
NMDAR antagonists. Thus, blockade of inclusion formation by memantine at higher 
concentrations, but not lower, most likely results from interrupting endogenous synaptic 
activity in these cultures. To further characterize the role of synaptic activity in mtHtt 
aggregation, we used two additional pharmacological tools to suppress normal excitatory 
synaptic transmission. Both tetrodotoxin (TTX, to block Na+ channels and thus the 
propagation of action potentials that lead to endogenous synaptic activity) and NO-711 (to 
block GABA uptake and hence augment inhibitory neurotransmission) decreased mtHtt-
containing inclusions (Fig. 1c). Taken together, our data suggest that interruption of normal 
excitatory synaptic activity (mediated by NMDARs) ameliorates macro inclusion formation.
Electrophysiological validation of pharmacological modifiers of synaptic activity
To confirm the notion that our pharmacological manipulations modified synaptic activity, 
we used whole-cell recording with patch electrodes to study spontaneous excitatory 
postsynaptic currents (sEPSCs). These experiments were designed to analyze the effect of 
short-term additions of drugs to determine their mechanism of action. The same drugs were 
used to prevent sEPSCs from triggering the intracellular signaling cascades involved in 
inclusion formation or neuronal cell death (Fig. 1; Supplementary Fig. 1). We found that 
total charge transfer during the NMDAR-mediated component of sEPSCs was significantly 
reduced by TTX or NO-711, in both wtHtt and mtHtt transfected cortical neurons (Fig. 2a, 
b). Similarly, high (30 μM) memantine significantly inhibited the NMDAR-mediated 
component of sEPSCs, while low (1-10 μM) memantine relatively spared this synaptic 
activity (Fig. 2c). In contrast, ifenprodil (10 μM) blocked this synaptic activity (Fig. 2d). 
However, in the presence of 10 μM CNQX, NMDAR-mediated synaptic activity was not 
significantly attenuated (Fig. 2e).
Additionally, both memantine (even at low concentrations), and ifenprodil, attenuated 
extrasynaptic NMDAR-mediated currents (Fig. 2f). The effect of low-dose memantine on 
extrasynaptic NMDAR-mediated currents was further confirmed by isolating extrasynaptic 
NMDAR activity using the previously published MK-801 protocol11 (Supplementary Fig. 5 
online). These electrophysiological findings validate the specificity of our pharmacological 
tools for NMDARs when studying mtHtt aggregation and neuronal cell death. Next, we 
examined whether NMDAR-sEPSCs were affected by mtHtt under our conditions. We 
found that total charge transfer during sEPSCs was not significantly different in mtHtt- vs. 
wtHtt-transfected neurons (Fig. 2g). Similar findings were observed in striatal slice 
recordings from the YAC72 mouse model of HD during low-frequency cortical afferent 
stimulation12, simulating the spontaneous activity level in our cultures. At higher levels of 
stimulation, mtHtt itself is known to enhance NMDAR activity6.
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Chaperonin TRiC facilitates synaptic activity-dependent inclusion formation
Next, we investigated the molecular mechanism of mtHtt-induced inclusion formation. 
Recently, three groups reported in yeast and cell lines that the chaperonin TRiC (TCP1 ring 
complex, also known as CCT) detoxifies mtHtt, at least in part by forming multiple mtHtt 
inclusions, while decreasing toxic soluble microaggregates of mtHtt and thereby decreasing 
toxicity13. Augmentation of TRiC activity increased the appearance of multiple, small 
mtHtt-containing inclusions (Fig. 3c and 5c in Tam et al.14), reminiscent of our findings in 
neurons with preserved synaptic activity (our Fig. 1a; Supplementary Figs. 1a and 3). Hence, 
we examined if synaptic activity regulates the expression of TCP1, the subunit of TRiC that 
preferentially interacts with mtHtt14. We added TTX to our neuronal cultures to block 
synaptic activity and found that it significantly reduced the expression of TCP1 (Fig. 3a). 
While low-dose memantine (10 μM) did not affect the TCP1 expression, both high-dose 
memantine (30 μM) and ifenprodil also decreased TCP1 levels (Supplementary Fig. 6 
online), supporting the notion that synaptic NMDAR activity is necessary for TCP1 
expression.
To test if TCP1 is involved in synaptic activity-induced inclusion formation, we generated 
two small hairpin RNA interference constructs (shRNAs designated TCP1 RNAi-1 and 
RNAi-2) to knockdown TCP1 expression. TCP1 RNAi-1 and RNAi-2 reduced TCP1 levels 
to 70% and 60%, respectively (Supplementary Fig. 7 online). Both small hairpin TCP1 
RNAi vectors significantly decreased inclusion formation from mtHtt (Fig. 3b). 
Additionally, knockdown of TCP1 by RNAi occluded the inhibitory effect on inclusion 
formation exerted by suppression of synaptic activity with high-dose (30 μM) memantine 
(Supplementary Fig. 8 online). Taken together, our results indicate that synaptic activity 
induces expression of TCP1, which in turn mediates inclusion formation in neurons. 
Moreover, TRiC has been reported to cooperate with the Hsp70 chaperone system15-17; 
Hsp70 attaches to mtHtt inclusions to protect cells from death17,18. Indeed, here we 
observed co-localization of inclusions and Hsp70 (Supplementary Fig. 9 online), suggesting 
that the TRiC-Hsp70 system might ameliorate mtHtt toxicity.
mtHtt renders neurons more vulnerable to excitotoxic insult via extrasynaptic NMDA 
receptors
We have thus shown that physiological synaptic NMDAR activity is necessary for macro 
inclusion formation in mtHtt-expressing neurons. However, the relationship of mtHtt-
induced inclusion formation and neurotoxicity in HD pathogenesis has remained 
contentious19,20. Large aggregates of abnormally folded proteins have been hypothesized 
to contribute to synaptic damage in neurodegenerative disorders21, but a recent report 
suggests that inclusion formation protects neurons from cell death22, possibly by decreasing 
the level of toxic soluble forms of mtHtt23. Neurodegeneration in HD has also been 
proposed to represent excitotoxic-mediated apoptotic cell death triggered by excessive 
activation of NMDARs24. Increased sensitivity to NMDAR-mediated excitotoxicity has 
been observed in the YAC128 mouse model of HD6. On the other hand, recent studies have 
indicated that physiological levels of synaptic NMDAR activity (predominantly composed 
of NR2A subunits in mature neurons) promote survival in the face of various forms of 
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stress11. The exact role of normal neuronal electrical activity in the pathogenesis of HD has 
not previously been studied.
Our observation that endogenous synaptic NMDAR activity promotes formation of mtHtt-
containing inclusions prompted our investigation of whether this normal activity could 
protect neurons. Conversely, we hypothesized that excessive activation of extrasynaptic 
NMDARs may increase neuronal vulnerability induced by mtHtt. To test this notion, we 
initially applied a relatively low concentration of exogenous glutamate (50 μM), which by 
itself was not excitotoxic to untransfected or wtHtt-transfected neurons under these 
conditions, to stimulate both extrasynaptic and synaptic receptors. While transfection of 
mtHtt by itself did not result in neuronal death, as shown previously6, we found that mtHtt 
neurons became more vulnerable in the presence of 50 μM glutamate (Fig. 4a-c). When 
mtHtt neurons were treated with memantine or ifenprodil, neuronal cell death induced by 
exogenous glutamate was significantly reduced. Of note, we found that low concentrations 
of memantine (1-10 μM), which selectively block excessive extrasynaptic NMDAR activity 
while sparing physiological synaptic NMDARs (Fig. 2; Supplementary Figs. 5 and 10 
online)9,10, were sufficient to protect mtHtt-transfected neurons from glutamate challenge. 
Additionally, extrasynaptic NMDARs preferentially contain NR2B subunits25, and 
ifenprodil, a relatively selective inhibitor of NR2B, blocked this neurotoxicity6,11. Taken 
together, these results imply that mtHtt renders neurons more vulnerable to acute excitotoxic 
insults and that blockade of extrasynaptic NMDARs efficiently ameliorates this excitotoxic 
cell death. In this regard, we observed similar results for both truncated (N-terminal 
fragment) (Fig. 4b) and full-length Htt constructs (Fig. 4c).
Physiological synaptic activity protects mtHtt expressing-neurons from cell death
Next, we examined the effect of normal synaptic activity on survival of neurons expressing 
mtHtt. We found that TTX, which suppresses normal excitatory synaptic transmission, or 
NO-711, which enhances inhibitory neurotransmission, triggered significant cell death in 
mtHtt- but not wtHtt-expressing neurons (Fig. 4d; Supplementary Fig. 11 online). We then 
asked if extrasynaptic NMDAR activity causes cell death in mtHtt neurons when protective 
(physiological) synaptic NMDAR activity is inhibited. Accordingly, we investigated if an 
NMDAR antagonist that preferentially blocks extrasynaptic activity could protect mtHtt 
neurons from toxicity induced by TTX or NO-711. Indeed, we found that treating mtHtt 
cultures with low concentrations (~5 μM) of memantine significantly reduced neuronal 
death induced by TTX or NO-711 (Fig. 4d). The question arises where the extrasynaptic 
glutamate originates in our culture system in the presence of neuronal activity blockade with 
TTX because synaptic release is inhibited. Since the intracellular pool of glutamate, used for 
metabolic purposes, may be significant, up to 10 mM per cell26, mtHtt-insulted neurons 
may potentially leak glutamate from nonsynaptic sites. Additionally, similar to the intact 
brain, our culture system contains nonneuronal cells, predominantly astrocytes. Even in the 
absence of synaptic activity, glutamate released from astrocytes can activate extrasynaptic 
NMDARs in neurodegenerative conditions27,28.
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Effect of electrical activity on the molecular pathways involved in inclusion formation and 
cell survival in mtHtt-expressing neurons
We next wanted to investigate the relationship of macro inclusion formation, electrical 
activity, and neuronal survival pathways. Since we had demonstrated earlier that TCP1 
mediates inclusion formation (Fig. 3b), we examined if TCP1 is involved in the survival of 
neurons expressing mtHtt. We found that knockdown of TCP1 not only decreased inclusion 
formation but also significantly increased neuronal cell death in mtHtt-expressing neurons 
(Fig. 4e). These RNAi experiments imply causality between TCP1 levels, inclusion 
formation, and neuronal cell death. Importantly, this form of cell death was significantly 
ameliorated by blockade of extrasynaptic NMDARs using low-dose memantine (Fig. 4e). 
Taken together, our results suggest that synaptic activity induces expression of TCP1, which 
in turn contributes to protective inclusion formation and decreased neurotoxicity. 
Conversely, blockade of synaptic activity reduces TCP1 levels, which in turn decreases 
mtHtt inclusion formation, and contributes to neuronal cell death in conjunction with 
excessive extrasynaptic NMDARs activity.
Additionally, using low-dose memantine, we investigated if the level of Rhes, a small 
guanine nucleotide-binding protein recently reported to mediate mtHtt sumoylation, 
disaggregation and cytotoxicity29, is affected by blockade of extrasynaptic NMDARs. We 
found that low-dose memantine (5-10 μM) reduced Rhes levels (Supplementary Fig. 12 
online), consistent with the notion that extrasynaptic NMDAR activity controls Rhes 
expression. Thus, the detrimental effects of excessive extrasynaptic NMDAR activity in the 
context of mtHtt may be ascribed, at least in part, to a relative increase in Rhes.
NMDAR activity modulates the neuroprotective CREB—PGC-1α pathway in neurons 
expressing mtHtt
CREB/CBP transcriptional activity, which triggers the neuroprotective PGC-1α pathway, 
has been shown to be decreased by extrasynaptic NMDAR activity11 as well as by binding 
to soluble mtHtt30. We therefore hypothesized that impairment of the CREB—PGC-1α 
cascade may contribute to neuronal cell death in HD31. Hence, we determined if CREB 
function was compromised in mtHtt-expressing neurons when synaptic activity was blocked. 
In mtHtt- but not wtHtt-transfected neurons we found a significant decrease in CREB 
activity in the presence of TTX, which suppresses excitatory synaptic activity (Fig. 4f). 
Additionally, blockade of extrasynaptic NMDARs with low concentrations of memantine 
restored CREB function, suggesting that mtHtt and activation of extrasynaptic NMDARs are 
necessary for CREB inactivation.
We next determined the level of PGC-1α under these same conditions. We observed a 
significant decrease in PGC-1α levels in mtHtt-transfected neurons in the presence of TTX, 
but preservation of PGC-1α levels in the presence of low concentrations of memantine (Fig. 
4g; Supplementary Fig. 13 online). Additionally, we found that RNAi knockdown of TCP1 
decreased CREB activity and PGC-1α levels in mtHtt-expressing neurons (Supplementary 
Fig. 14 online). These findings support the notion that mtHtt in the absence of TCP1, in 
conjunction with excessive extrasynaptic NMDAR activity, interferes with the 
neuroprotective CREB—PGC-1α cascade. Importantly, decreased levels of PGC-1α likely 
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contribute to cell death in mtHtt-transfected neurons exposed to TTX (and thus in neurons 
with blocked synaptic activity and decreased mtHtt inclusions). As would be predicted, cell 
death under these conditions was diminished by co-transfection with PGC-1α (Fig. 4d).
NMDAR activity modulates toxicity and behavior in HD transgenic mice
These findings raise the possibility that long-term blockade of extrasynaptic activity would 
be advantageous while simultaneous blockade of synaptic activity might prove deleterious in 
vivo, for example, in the transgenic YAC128 HD mouse8 (Supplementary Fig. 4b). We 
hypothesized that the balance between synaptic and extrasynaptic activity in the face of 
mtHtt would determine neuronal survival. Therefore, while short-term blockade of both 
synaptic and extrasynaptic activity might cause transient improvement, eventually blockade 
of synaptic activity would lead to neuronal loss. In contrast, maintenance of synaptic activity 
with abrogation of excessive extrasynaptic activity would be most beneficial to combat the 
deleterious effects of mtHtt. To test this hypothesis in vivo, YAC128 mice were treated 
using drinking water with low-dose memantine (1 mg kg-1) to block extrasynaptic NMDAR 
activity or high-dose memantine (30 mg kg-1) to additionally block synaptic NMDAR 
activity since we knew that these doses would produce low and high concentrations of 
memantine approaching those used in the culture experiments9,10,32-34. Treatment 
commenced at 2 months of age and continued for 10 months until 12 months of age. We 
first analyzed mtHtt inclusions using immunostaining with antibody EM48, which 
recognizes N-terminal huntingtin and is highly specific for aggregates35. Treatment with 
low-dose memantine increased inclusion formation (Fig. 5a, b), as confirmed using a filter 
trap assay (Supplementary Fig. 15 online), while high-dose memantine significantly 
decreased inclusion formation in 12-month-old YAC128 mice (Fig. 5a, b). Accordingly, 
high-dose memantine also increased soluble mtHtt (Supplementary Fig. 16 online). These 
effects of memantine treatment on inclusion formation were not due to alterations in mtHtt 
protein expression since low and high doses of memantine did not affect mtHtt levels 
(Supplementary Fig. 17 online). On the other hand, TCP1 levels increased with low-dose 
memantine and decreased with high-dose memantine (Supplementary Fig. 18 online), 
supporting the notion that normal synaptic NMDAR activity increases TCP1 and promotes 
inclusion formation.
Next, we measured loss in striatal volume in YAC128 mice, a cardinal neuropathological 
feature of HD36. Low-dose memantine improved striatal volume, while high-dose 
memantine worsened this parameter (Fig. 5c). These findings support our hypothesis that 
maintenance of synaptic activity, while inhibiting excessive extrasynaptic activity, is 
protective, and that long-term blockade of synaptic activity is detrimental. We also 
monitored motor function by rotatrod testing at 12 months of age. YAC128 HD mice treated 
with low-dose memantine demonstrated improvements on these motor tests, while high-
dose-treated mice showed no improvement (Fig. 5d). Taken together, these results support 
the premise that maintenance of synaptic activity with abrogation of extrasynaptic activity is 
beneficial in YAC128 HD mice.
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DISCUSSION
Our results provide a mechanistic framework to help us understand the selective 
vulnerability of striatal and cortical neurons in HD. We show here that synaptic activity 
controls expression of the chaperonin TRiC, which in turn modulates inclusion formation 
and toxicity of mtHtt. Moreover, the electrical properties of these neurons coupled with the 
predominant effect of the small guanine nucleotide-binding protein Rhes and the CREB—
PGC-1α pathway in this cell type29,37 renders them particularly sensitive to the toxic 
effects of mtHtt. Specifically, excessive extrasynaptic activity increases the relative Rhes 
level and, in conjunction with mtHtt, decreases CREB—PGC-1α activity to promote 
neuronal cell death. Coupled with a decrease in synaptic transmission, which also 
contributes to a decrease in CREB activity in the presence of mtHtt, neurons become 
increasingly vulnerable to injury and death (Fig. 6). We speculate that these findings imply 
that therapies for HD that minimize excessive extrasynaptic activity while maintaining or 
enhancing normal synaptic activity will yield considerable benefit. Notably, it has been 
contentious whether mtHtt inclusions are cytotoxic. The presence of inclusions may reflect 
either successful sequestration of toxic soluble oligomers of mtHtt and thus contribute to 
neuroprotection, or insufficient sequestration of toxic soluble mtHtt, which can no longer be 
accommodated by the inclusion formation process, and is thus toxic. Here, we report that 
synaptic activity-driven inclusions are neuroprotective, supporting the former premise.
Nonetheless, we also demonstrate that cultured neurons containing mtHtt inclusions become 
increasingly vulnerable to excitotoxic insults, consistent with the notion that over time, 
accumulation of excitotoxic challenges may eventually contribute to the death of mtHtt-
expressing neurons in HD6. We show not only that mtHtt increases the vulnerability of 
neurons to relatively low concentrations of exogenous glutamate, but also that suppressing 
spontaneous excitatory synaptic activity can mimic this phenomenon via the excitotoxic 
effect of endogenous glutamate apparently acting on extrasynaptic receptors.
Our data using primary neurons manifesting synaptic activity may also explain why others 
had reported direct mtHtt toxicity in the absence of excitotoxic insult in yeast, various cell 
lines, and synaptically-immature neurons. That is, the presence of normal synaptic activity 
in our mature neuronal cultures leads to the formation of inclusions, thereby avoiding toxic 
oligomers of mtHtt, whereas these other cell types lack synaptic activity and therefore are 
exposed to soluble mtHtt oligomers.
Our findings further suggest that the balance between synaptic and extrasynaptic NMDAR 
activity may be critical in determining neuronal cell survival in HD. We show that low 
concentrations of the NMDAR antagonist, memantine, afford the advantage of restoring 
excitatory balance by maintaining physiological synaptic activity while blocking excessive 
extrasynaptic NMDAR stimulation9,10. Inhibiting excessive extrasynaptic NMDAR activity 
decreased Rhes levels, thus preserving mtHtt inclusions and lessening mtHtt cytotoxicity29. 
To the contrary, blocking synaptic activity with high-dose memantine decreased inclusion 
formation and increased soluble mtHtt. Soluble mtHtt interferes with the neuroprotective 
CREB—PGC-1α pathway, thus accelerating neuronal cell death. Indeed, prolonged 
administration of high-dose memantine may contribute to toxicity for several reasons, 
Okamoto et al. Page 8
Nat Med. Author manuscript; available in PMC 2010 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
including interference with other neuroprotective pathways that are dependent on synaptic 
activity, such as the phosphatidylinositol 3 kinase (PI3K)-Akt cascade38,39. Thus, we posit 
that restoring excitatory balance, which is disrupted by mtHtt protein, can affect protein 
misfolding and protect neurons in HD, as also suggested in a small, open-label human 
clinical trial of memantine in HD patients40. This novel concept of balancing synaptic and 
extrasynaptic neuronal NMDAR activity may also lead to strategies to combat cell injury 
and death associated with other neurodegenerative disorders.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix
ONLINE METHODS
Cell culture and transfection
Primary cerebrocortical or striatal cultures, containing both neurons and glia, were made 
from E16 rat pups and grown on 12-mm glass coverslips, as we have described41. Cells 
were transfected via LipofectAMINE 2000 (Invitrogen) on the 15-20th DIV with either N-
terminal fragments of Htt consisting of exon 1 (Myc-wtHtt-N63-18Q or Myc-mtHtt-
N63-148Q), or with full-length Htt (wtHtt with 15Q or mtHtt with 138Q). In a number of 
experiments, cells were co-transfected with enhanced green fluorescence protein (EGFP) to 
facilitate identification of transduced cells. Labeled cells could be subsequently stained with 
anti-NeuN or anti-MAP-2 antibody, verifying their neuronal identity. In a series of 
experiments, a PGC-1α expression vector (ATCC) was also co-transfected. Transfection 
efficiency was 10-15% for cortical neurons, and 5-10% for striatal neurons. In experiments 
manipulating synaptic activity, drugs were added to cultures five hours post transfection. 
Extracellular Mg2+ was set at ≤ 0.4 mM to produce spontaneous NMDAR activity in the 
absence of excessive AMPAR stimulation, as assessed by patch-clamp recordings42. CREB 
transcriptional activity was analyzed using a CRE luciferase reporter (Stratagene) and renilla 
luciferase internal control vector (Promega), as previously described41. siSTRIKE plasmids 
expressing shRNAs targeting TCP1 and a non-targeted sequence were constructed according 
to the manufacturer’s protocol (Promega). TCP1 shRNA targeting the sequences were 
designed using Promega’s siRNA Target Designer.
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Assessment of inclusion formation and neuronal cell death
For assessment of inclusions, Htt-transfected cortical or striatal neurons were stained with 
anti-myc (for truncated N-terminal Htt constructs, Santa Cruz), or anti-huntingtin (for full-
length Htt constructs, Chemicon) to visualize huntingtin expression under deconvolution 
microscopy. The expression level of transfected full-length Htt was sufficiently above 
baseline to allow us to easily distinguish transfected from endogenous Htt (Supplementary 
Fig. 3). Images were captured with a Zeiss Axiovert 100M microscope equipped with 
deconvolution software (see Supplementary Methods).
Inclusion formation was assessed 15-17 h after drug application. Immunocytochemistry for 
MAP2 (Sigma) and NeuN (Chemicon) were used to identify neurons. The total number of 
transfected neurons with Htt-positive inclusions and the total number of transfected neurons 
on each coverslip were counted. In a series of experiments combining inclusion and 
neuronal cell death analysis, wtHtt or mtHtt was co-transfected with EGFP, the latter to 
facilitate identification of transduced cells; in this manner, we could normalize the number 
of viable, dead, or inclusion-containing neurons to the total number of transfected neurons 
for each treatment paradigm. In the cell death experiments, wtHtt- or mtHtt-expressing 
neurons were incubated in media with or without 50 μM glutamate for 40 h. In another 
series of experiments, cultures were incubated for 20 h with TTX or NO-711. In some 
experiments, PGC-1α was also expressed. Cells were then stained with anti-MAP2/anti-
NeuN, anti-myc antibodies, anti-PGC-1α antibody (Santa Cruz), anti-TCP1 antibody (Santa 
Cruz), and Hoechst dye 33342. Neuronal cell death was assessed on the basis of condensed 
nuclear morphology (with Hoechst dye) and shrunken neurites. Neurons were scored as 
viable if they possessed normal nuclei and neuritic processes30. In the assessment of both 
inclusion formation and neuronal cell death, for each experimental condition, ≥100 neurons 
were counted on triplicate coverslips, and the experiments were repeated at least four times; 
thus, n ≥ 1200 in each case. Data are expressed as mean ± s.e.m., and statistical significance 
was determined using an ANOVA followed by Dunnett’s post-hoc test.
Electrophysiological recordings
Whole-cell recordings were performed with an Axopatch 200B amplifier (Axon 
Instruments) from EGFP-positive neurons 48 to 96 h after transfection42. The extracellular 
solution contained (in mM): NaCl 135, KCl 2.5, CaCl2 2, MgCl2 0-0.01, NaHCO3 1, 
Na2HPO4 0.34, KH2PO4 0.44, glucose 20, Hepes 10, pH 7.4. Patch electrodes with a final 
tip resistance of 4-7 MΩ, were filled with a solution containing (in mM): CsCl 120, 
tetraethylammonium chloride (TEA-Cl) 20, Hepes 10, EGTA 2.25, CaCl2 1, MgCl2 2, and 
phalloidin 0.001, pH 7.4. To examine NMDAR-mediated sEPSCs, we used “charge 
transfer.” Details of this analysis are given in the Analysis of NMDAR-mediated sEPSCs 
section in the Supplementary Methods and in Supplementary Fig. 10. pCLAMP 8-9.2 
software (Axon Instruments) was used for data acquisition and analysis. All recordings were 
made at room temperature with a holding potential of -60 mV. Currents were digitally 
sampled at 10-20 kHz and filtered at 2-5 kHz. Data are expressed as mean ± s.e.m., and 
statistical significance was determined using a Student’s t-test for pairwise comparisons.
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Transgenic YAC128 HD mice
Male and female YAC128 mice expressing expanded human huntingtin with 128 CAG 
repeats and WT littermates maintained on the FVB/N strain (Charles River) were used for 
these experiments8,43. Mice were housed singly or in pairs in duplex cages with littermates 
of mixed genotype and maintained under a 12 L:12 D light cycle (lights on at 2300) in a 
clean facility and given free access to food and water. Experimenters were blind to the 
genotype of the mice. All experiments were performed with the approval of the animal care 
committee at the University of British Columbia.
Drug treatment
For administration of drugs in the drinking water, water consumption of individual cages 
was monitored on a biweekly-basis along with animal body weights. The concentrations of 
drug solutions for each cage were then adjusted accordingly. The drug solutions were 
replaced twice/week and provided ad libitum. Animals were treated starting at 2 months of 
age with 1 mg kg-1 day-1 to 30 mg kg-1 day-1 of memantine for 10 months, and their 
neuropathology and motor function was assessed at 12 months of age. The apparent 
effective concentration of memantine at the NMDAR-associated channel in vivo under these 
conditions after administration of low-dose memantine was estimated to be in the range of 
5-10 μM based on our current observations (see Supplementary Methods).
Assessment of motor function
Training and baseline testing for motor function tasks were carried out prior to memantine 
treatment initiation at 2 months of age during the dark cycle. Assessment of the effect of 
long-term (10-month) treatment with memantine on motor function was carried out by 
testing at 12 months of age. Motor coordination and balance were assessed using 
accelerating and fixed-speed rotarod tasks (UGO Basile, Comerio, Italy). In the accelerating 
task, the rotarod sped up from 5 revolutions per minute (RPM) to 40 RPM over 4 minutes. 
In the fixed task, the rotarod revolved at 24 RPM. Performance in the rotarod tasks was 
assessed by the amount of time that a mouse could remain running on the rotarod. During 
training, mice were given three trials per day for three consecutive days.
Neuropathological analysis
A series of 25 μm-thick coronal sections spaced 200 μm apart spanning the striatum was 
stained with NeuN antibody (Chemicon) overnight at room temperature, followed by 
incubation with biotinylated anti-mouse antibody (Vector Laboratories, Burlingame). The 
signal was amplified with an ABC Elite kit (Vector) and detected with diaminobenzidine 
(DAB; Pierce). Striatal volumes were determined from a series of mounted sections using 
StereoInvestigator software (Microbrightfield) by tracing the perimeter of the striatum in 
serial sections spanning the striatum.
Assessment of huntingtin inclusions in vivo
Perfused brain sections of 25 μm thickness from WT, untreated YAC128, 1 mg kg-1- and 30 
mg kg-1-treated YAC128 animals were immunoassayed with the antibody EM48 to assess 
the presence of mtHtt inclusions, as described previously35. Polyclonal EM48 antibody was 
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used at 1:500 and DAB was used as the chromogen (Vector). Htt inclusions were defined as 
EM48-positive staining at the light microscope level. Photographs of mounted sections were 
taken on a light microscope (Zeiss) under a 100X objective using a MetaMorph Imaging 
System (Molecular Devices), and the intensity of the staining of striatal neurons was 
measured.
Statistical analysis
Data are expressed as mean ± s.e.m. When suitable, results were interpreted using a one-way 
ANOVA with a Student-Newman-Keuls (SNK) post-hoc test. Pairwise comparisons 
between genotypes/treatments were assessed with a Student’s t-test. Differences were 
considered statistically significant at P < 0.05.
Additional methods
Supporting methodology is described in the Supplementary Methods.
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Figure 1. 
Suppression of excitatory NMDAR synaptic transmission ameliorates inclusion formation in 
mtHtt-expressing neurons. (a, b) Immunostaining and quantification of inclusion bodies in 
rat primary cortical neurons transfected with wtHtt (Myc-wtHtt-N63-18Q) or mtHtt (Myc-
mtHtt-N63-148Q) after treatment with AMPA receptor antagonist CNQX (10 μM) or with 
NMDAR antagonists memantine (10 μM or 30 μM), D-APV (150 μM), or ifenprodil (10 
μM), a relatively selective inhibitor of NR2B subunits of the NMDAR. Values are mean ± 
s.e.m. (n ≥ 1,200). Scale bar, 10 μm. *, P < 0.01 by ANOVA. (c) Inclusion formation was 
quantified in rat primary neurons transfected with wtHtt or mtHtt and treated with synaptic 
activity suppressors (0.2 μM TTX or 100 μM NO-711). Values are mean ± s.e.m. *, P < 0.01 
by ANOVA.
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Figure 2. 
Pharmacology of NMDAR-mediated sEPSCs and whole-cell currents recorded from wtHtt- 
and mtHtt-transfected neurons. (a-e) sEPSCs (left-hand panels) and charge transfer (right-
hand panels), normalized for each cell (see Supplementary Methods). Both wtHtt- and 
mtHtt-transfected neurons were treated with TTX (a), NO-711 (b), memantine (c), or 
ifenprodil (d). Recording solutions in (a-e) contained 20 μM glycine; for (c. d), CNQX and 
bicuculline (10 μM each) were also added. Values are mean ± s.e.m. (n ≥ 4 cells in each 
case); *, P < 0.03 (paired t-test on raw data). (f) Effects of memantine and ifenprodil on 
extrasynaptic NMDAR-mediated currents. Incomplete reversal was observed because of 
slow washout in this system. Recordings were performed in the presence of 0.1-1 μM TTX. 
NMDA currents were evoked by co-application of 100 μM NMDA and 20 μM glycine. (g) 
Charge transfer (fC/pF) for NMDAR-sEPSCs in mtHtt- and wtHtt-transfected neurons.
Okamoto et al. Page 16
Nat Med. Author manuscript; available in PMC 2010 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. 
Involvement of the chaperonin TRiC TCP1 subunit in synaptic activity-mediated inclusion 
formation. (a) Immunoblotting demonstrating the level of TCP1 protein expression in 
neurons exposed to TTX (0.2 μM) or control conditions for 24 h. Actin served as a loading 
control. (b) Inclusion formation was quantified in neurons transfected with mtHtt plus two 
different small hairpin vectors for TCP1 or control vector. Values are mean ± s.e.m. for n ≥ 
300. *, P ≤ 0.001 by ANOVA.
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Figure 4. 
Excitatory synaptic versus extrasynaptic activity in HD-related neuronal cell death. (a) 
Excessive glutamate insult (50 μM for 40 h) led to neuronal cell death in mtHtt-transfected 
cortical neurons in the presence of inclusion formation (scale bar, 10 μm). Neurons 
transfected with mtHtt contained inclusions and displayed healthy nuclei. (b, c) Cell death 
analysis after transfection with the N-terminal fragment of mtHtt (b) and full-length mtHtt 
(c). Values represent mean ± s.e.m. for n ≥ 1,200. *, P < 0.01 by ANOVA. (d) Memantine 
attenuated neuronal cell death induced by blockade of physiological excitatory synaptic 
activity with NO-711 or TTX in mtHtt-transfected neurons. Co-transfection of PGC-1α 
mitigated neuronal cell death induced by blockade of synaptic activity with TTX. Values 
represent mean ± s.e.m. for n ≥ 1,200. *, P < 0.05; **, P < 0.01 by ANOVA. (e) Cell death 
was quantified in neurons transfected with wtHtt or mtHtt plus two different small hairpin 
vectors for TCP1 or a control vector. Values are mean ± s.e.m. for n ≥ 300. *, P ≤ 0.01 by 
ANOVA. (f) Low concentration (5 μM) memantine abrogated the decrease in CREB activity 
induced by blockade of physiological excitatory synaptic activity with TTX in mtHtt-
transfected neurons. Neurons were transfected with a CRE-luciferase reporter construct and 
wtHtt or mtHtt. Ordinate axis represents relative luciferase activity. Values represent mean ± 
s.e.m. *, P < 0.01 by ANOVA. (g) Low concentration memantine ameliorated the decrease 
in PGC-1α levels induced by blockade of synaptic activity with TTX in mtHtt-transfected 
neurons. PGC-1α levels were quantified by immunofluorescence under deconvolution 
microscopy in wtHtt- or mtHtt-transfected neurons. Values represent mean ± s.e.m. for n ≥ 
300. *, P < 0.01 by ANOVA.
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Figure 5. 
Long-term treatment with memantine affects neuropathology and motor function in a dose-
specific manner in transgenic YAC128 HD animals. (a) The extent of inclusion formation 
was assessed using unbiased densitometry of striatal neurons stained with EM48. (b) 
Representative immunohistological photographs of EM48-stained striata from WT, 
untreated YAC128 animals, and YAC128 animals treated with 1 or 30 mg kg-1 memantine. 
The photomicrographs were taken using an 100x objective (scale bar, 50 μm). (c) Striatal 
volumes were determined by tracing the perimeter of the striatum in serial sections spanning 
the striatum. (d) Effects of low-dose or high-dose memantine on the fixed-speed (left) or 
accelerating rotarod task (right) in YAC128 animals. Values represent the mean change 
from baseline latency to fall. Data represent mean + s.e.m. *, P < 0.05; **, P < 0.01; ***, P 
< 0.001.
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Figure 6. 
Schematic model showing the role of physiological synaptic vs. excessive extrasynaptic 
NMDAR activity in the neurodegeneration of Huntington’s disease. Physiological synaptic 
NMDAR activity promotes neuroprotection, in part by facilitating non-toxic aggregation of 
mtHtt via the chaperonin TRiC. Otherwise toxic mtHtt would interfere with the 
neuroprotective CREB-PGC-1α pathway. In contrast, extrasynaptic NMDAR activity 
promotes neuronal cell injury and death, in part by increasing the relative level of Rhes, and, 
in conjunction with soluble/toxic mtHtt, by contributing to transcriptional deregulation of 
the CREB-PGC-1α cascade. Drugs inhibiting extrasynaptic or synaptic activity are 
indicated. Note that most NMDAR antagonists, as well as high concentrations of 
memantine, block both synaptic and extrasynaptic NMDAR-mediated currents, while low 
concentrations of memantine block predominantly the extrasynaptic component, thus 
relatively sparing synaptic activity and promoting neuroprotection.
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